The EPI-CE test is a simple urine test that detects three important genomic biomarkers that are markers of high-grade prostate cancer. Using this assessment, the physician can determine whether or not a patient should undergo a diagnostic biopsy.
Gaining access to molecular information from biofluids without needing direct access to the tissue itself will have far-reaching implications in patient management. While our diagnostics are initially focused on cancer, our exosome-based technology platform is potentially applicable to other diseases or medical conditions where molecular testing is beneficial, but where access to tissue is difficult or impossible.
"Understandably, having a prostate biopsy performed is associated with a great deal of anxiety for the patient. Practice shows that many biopsies are not performed even though a cancer would have been present. And at the same time, biopsies are performed that would not have been necessary. The Exosome test aids the biopsy decision enormously and increases confidence with both patients and physicians." - Dr. Mikkel Noerholm, Laboratory Director, Head of EU Operations: